| Identification | Back Directory | [Name]
Olinvacimab | [CAS]
2095504-49-5 | [Synonyms]
Olinvacimab
Tanibirumab
Research Grade Olinvacimab (DHE16602)
Research Grade Tanibirumab (DHE16604) |
| Hazard Information | Back Directory | [Uses]
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer[1]. | [in vivo]
Olinvacimab (100 ng; s.c., once) inhibits angiogenesis in vivo[1]. | Animal Model: | Matrigel-implanted nude mice model[1] | | Dosage: | 100 ng | | Administration: | Subcutaneous injection; 100 ng, once | | Result: | Inhibited the neovascularization induced by hVEGF165. |
| [References]
[1] Lee WS, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs. 2015;7(5):957-68. DOI:10.1080/19420862.2015.1045168 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|